share_log

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3

Benzinga Real-time News ·  Nov 14, 2022 07:36

Wells Fargo analyst Yanan Zhu maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Equal-Weight and raises the price target from $1.5 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment